Vincenzo Brando

University of Turin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

P. Gabriele

Fondazione Piemontese per la Ricerca sul Cancro Onlus

Mario Airoldi

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Fulvia Pedani

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Roberto Orecchia

European Institute of Oncology

Giovanni Succo

University of Turin

A Cavalot

IRCCS Humanitas Research Hospital

João Calisto

Hospitais da Universidade de Coimbra

R Orecchia

European Institute of Oncology

Maria Grazia Ruo Redda

University of Turin

Carlo Giordano

University of Turin

Cooperative Institutions

University of Turin

Hospitais da Universidade de Coimbra

Azienda Ospedaliero Universitaria San Giovanni Battista

Fondazione Ricerca Molinette

Istituti di Ricovero e Cura a Carattere Scientifico

University of Milan

Universidade de São Paulo

University of Coimbra

Candiolo Cancer Institute

Politecnico di Milano

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Comparison of methotrexate and sequential methotrexate-5-fluorouracil for patients with recurrent squamous cell carcinoma of the oral cavity.

PubMed (1987)

Mario Airoldi Fulvia Pedani Vincenzo Brando P. Gabriele Roberto Orecchia

Forty-eight fully assessable previously treated patients with biopsy-proven recurrent squamous cell carcinoma of the oral cavity were randomized to receive either methotrexate (MTX), 40 mg/m2 iv push weekly, or sequential MTX and 5-fluorouracil (5-FU) (MTX 150 mg/m2 iv for 1 h; 1 h after the end of MTX, 5-FU 600 mg/m2 iv for 2 h; 24 h later, leucovorin rescue 10 mg/m2 iv and the same dose was given orally every 6 h 4 times; the treatment was repeated every 10 days). There were 1 complete response (CR) and 5 partial responses (PR) in the MTX group; median remission duration = 84 days. There were 3 CR and 11 PR in the MTX-5-FU group (overall response 14/24, 58.3%--p less than 0.05); median remission duration = 125 days. Median survival was 6.2 months in the MTX group and 8.1 months in the MTX-5-FU group. There was no difference in mucositis between the two groups, and a prevalence of leukopenia and moderate gastro-intestinal toxicity in the MTX-5-FU group.

Mucositis

Leukopenia

Source

Cite

Citations (5)

Combined Chemotherapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

Journal of Chemotherapy (1989)

Mario Airoldi Fulvia Pedani P. Gabriele C. Giordano A Cavalot

Thirty-two patients (24 males, 8 females; median age 54 yrs) with recurrent and/or metastatic undifferentiated carcinoma of the nasopharyngeal type were treated with chemotherapy. Remissions were observed in 17 of 32 (53.2%) with 5 complete (CR) (15.6%) and 12 partial responses (PR) (37.6%). A combination of cisplatin and 5-fluorouracil was the most effective regimen (CR + PR = 83.3%). Objective responses. (CR + PR) were 47% (CR = 11.7%) in schemes without cisplatin and 60% (CR = 20%) in cisplatin-based combinations. The median overall duration of response was 7.2 months. The median overall survival time was 10.3 months: 15.1 months for responders and 5.2 for non-responders. No important toxicity was observed.

Regimen

Combination chemotherapy

10.1080/1120009x.1989.11738907

Cite

Citations (9)

CDDP+5-FU and reirradiation in the treatment of locally recurrent head and neck cancer

European Journal of Cancer (1993)

Mario Airoldi Roberto Orecchia Vincenzo Brando P. Gabriele

10.1016/0959-8049(93)91419-l

Cite

Citations (0)

Small Bowel Metastasis from Squamous Cell Carcinoma of the Larynx. A Case Report

Tumori Journal (1993)

Mario Airoldi P. Gabriele Giovanni Succo Guido Valente Vincenzo Brando

Small bowel metastases from squamous cell carcinoma of the head and neck are relatively rare and in some cases asymptomatic. In the case herein reported, small bowel metastasis from a laryngeal carcinoma caused a life-threatening complication. The surgical approach was effective in saving the patient's life. Death occurred for neck tumor progression without abdominal signs of secondary lesions. A review of the previously reported cases is provided.

10.1177/030089169307900414

Cite

Citations (9)

4.48 Post-revascularization ischaemia determined by myocardial perfusion scintigraphy: clinical and epidemiological predictors

Journal of Nuclear Cardiology (2001)

Pedro Monteiro Leopoldo Pisanelli Rodrigues de Oliveira Maria Beatriz Cardoso Ferreira A.I. Ferrer-Antunes Vincenzo Brando

10.1016/s1071-3581(01)80548-1

Cite

Citations (0)

Undifferentiated nasopharyngeal-type carcinoma in a nurse handling cytostatic agents

European Journal of Cancer Part B Oral Oncology (1993)

P. Gabriele Mario Airoldi Giovanni Succo Vincenzo Brando Maria Grazia Ruo Redda

10.1016/0964-1955(93)90040-l

Cite

Citations (7)

Cisplatin, Epirubicin and 5-Fluorouracil Combination Chemotherapy for Recurrent Carcinoma of the Salivary Gland

Tumori Journal (1989)

Mario Airoldi Fulvia Pedani Vincenzo Brando P. Gabriele Carlo Giordano

Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen. Previous therapy included surgery (1 case), radiotherapy (1 case), and surgery + radiotherapy (7 cases). There was 1 complete response (11.1%), 3 partial responses (33.3%), 2 unchanged lesions (22.2%) and 3 progressions (33.3%). Patients with local recurrence had a better response. Median remission duration was 7.5 months in CR + PR patients. Median overall survival was 8+ months; 14+ months for responders and 4 months for nonresponders. The major toxic effects were nausea/vomiting and alopecia; myelosuppression was less frequent and usually not severe.

Epirubicin

Regimen

Adenoid Cystic Carcinoma

10.1177/030089168907500312

Cite

Citations (34)

Chemotherapy for Recurrent Salivary Gland Malignancies: Experience of the ENT Department of Turin University

ORL (1994)

Mario Airoldi Vincenzo Brando Carlo Giordano P. Gabriele Mario Bussi

Twenty-seven patients (17 males, 10 females; median age 59 years) with recurrent high-grade malignancies of major (22 cases) and minor (5 cases) salivary gland origin (10 adenoid cystic carcinomas, 9 adenocarcinomas, 4 poorly differentiated carcinomas, 1 mixed malignant tumor, 3 mucoepidermoid carcinomas) were treated by monochemotherapy – cisplatin (CDDP) in 8 cases, or adriamycin in 5 cases – or polychemotherapy – CDDP + epirubicin + 5-fluorouracil/cyclophosphamide in 9 cases or CDDP + 5-fluorouracil in 3 cases with mucoepidermoid carcinomas. In adenocarcinoma-like tumors, patients treated by polychemotherapy showed a better response (9.1 % CR, 36.3% PR) than patients treated with monochemotherapy (no CR, 23% PR). Patients with local recurrence and adenocarcinoma exhibited a better response. Median response duration: 7.5 months after poly- and 4 after monochemotherapy. Median overall survival time was 8+ months (responders: 14+) in the polychemotherapy group and 5.5 (responders: 8) in the monochemotherapy group. In the 3 cases with mucoepidermoid carcinoma 1 patient achieved a PR (33.3%) and in 2 there was no change.

Epirubicin

Adenoid Cystic Carcinoma

10.1159/000276620

Cite

Citations (19)

Polychemotherapy in the treatment of recurrent carcinoma of the paranasal sinuses

European Journal of Cancer (1993)

Vincenzo Brando Mario Airoldi P. Gabriele R Orecchia

10.1016/0959-8049(93)91420-p

Cite

Citations (0)